CME Presentations

BRAF Melanoma


Presentations


Speakers

  • Jeffrey S. Weber, MD, PhD

    Jeffrey S. Weber, MD, PhD

    Jeffrey S. Weber, MD, PhD

    Jeffrey S. Weber, MD, PhD, is deputy director of the Laura and Isaac Perlmutter Cancer Center (PCC), co-director of PCC’s Melanoma Research Program, and professor of medicine at NYU Langone Medical Center in New York. His clinical and research interests lie in the field of immunotherapy for cancer, which have allowed him to publish over 220 articles in top peer-reviewed journals in his field. Dr Weber has been involved in many clinical trials, including trials for melanoma vaccines, protocols for adoptive cell therapy, and novel immunotherapy trials for melanoma patients. He is the chair of the CONC study section of the National Cancer Institute, and sits on the scientific advisory boards of 5 cancer-related biotechnology companies and numerous cancer institutions and foundations.
  • Vernon Sondak, MD

    Vernon Sondak, MD

    Vernon Sondak, MD

    Vernon K. Sondak, MD, is chair of the Department of Cutaneous Oncology at the H. Lee Moffitt Cancer Center and Research Institute, and professor in the Departments of Oncologic Sciences and Surgery at the University of South Florida Morsani College of Medicine in Tampa. His research interests, which have allowed him to author or coauthor over 420 articles in peer-reviewed publications, include surgical treatment, and adjuvant and neoadjuvant therapy of melanoma. Dr Sondak has received numerous awards, including the Golden Scalpel Award from the UCLA Division of General Surgery. He is a member of the National Cancer Institute’s Board of Scientific Counselors for Clinical Sciences and Epidemiology and is North American Vice President of the Melanoma World Society.

CME Information

BRAF-Mutated Melanoma: Optimizing Treatment & Addressing Challenges in the Adjuvant and Metastatic Settings


PIM LogoPQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Evaluate the timing and importance of BRAF testing at diagnosis to facilitate treatment decision-making
  • Compare and contrast safety and efficacy data for immunotherapies and BRAF/MEK therapies for the management of Stage III and IV melanoma
  • Identify strategies to monitor and evaluate adverse events associated with current and emerging combination approaches
Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC in collaboration with the Melanoma Research Foundation.

ACKNOWLEDGEMENT

This activity is supported by educational grants from Bristol-Myers Squibb Company.

TUITION

Complimentary

JointlyAccreditedProvider Logo

JOINT ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

LIVE CREDIT DESIGNATION STATEMENTS

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2139-L01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.

Enduring Credit Designation Statements
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

(Universal Activity Number - JA4008162-9999-20-2140-H01-P)

Type of Activity: Knowledge

Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1 contact hours.

Date of Release/Expiration
Live Activity
June 26, 2020
• 12:00pm – 1:00pm ET: BRAF-Mutated Melanoma: Optimizing Treatment & Addressing Challenges in the Adjuvant and Metastatic Settings

Enduring Material:
The enduring material will be available from June 26, 2020 – June 26, 2021.

TARGET AUDIENCE

Medical oncologists, dermatologists, surgical oncologists, pathologists, general surgeons, oncology nurse practitioners/physician assistants, and other clinicians involved in the diagnosis and treatment of melanoma.

ESTIMATED TIME TO COMPLETE

This activity consists of one session which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To participate in the activity, go to www.OMedLive.com. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

For Pharmacists: Upon receipt of the completed activity evaluation form credit will be submitted to the NABP CPE Monitor Service.

Pharmacists will need to provide their National Association of Boards of Pharmacy (NABP) e-Profile ID and date of birth (MMDD) to ensure the data is submitted to the ACPE and NABP properly. If you need to obtain your NABP e-Profile, please visit www.nabp.net.

HARDWARE / SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Jeffrey S. Weber, MD, PhD Receipt of Intellectual Property Rights/Patent Holder: Named on a PD-I bio marker patent by Biodesix, and a CTLA4 biomarker patent by Moffitt Cancer Center
Consulting Fees: BMS, GSK, Merck, Novartis, Array, Pfizer, Genentech, Astra Zeneca
Ownership Interest less than 5%: Immunimax, CytoMx, Biond
Vernon Sondak, MD Consulting Fees:
Bristol-Myers Squibb, Merck, Novartis, Polynoma, Regeneron

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Tariqa Ackbarali Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Bridget Griffin, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable):

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.